Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury
Sponsor: University of California, San Francisco
Summary
The goal of this pilot clinical trial is to learn if early restart of renin-angiotensin system inhibitor (RASi) medications is feasible and well-tolerated in hospitalized patients with acute kidney injury (AKI). Researchers will compare early RASi restart to usual care. Study participants will restart RASi per study protocol, obtain a lab test in 1-2 weeks if RASi restarted in the hospital and not collected as part of routine care, and answer questions at the 90-day follow-up.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-08
Completion Date
2029-03
Last Updated
2026-07-29
Healthy Volunteers
No
Conditions
Interventions
Early RASi restart strategy
The early restart strategy is to resume RASi as soon as the serum creatinine (SCr) downtrends by ≥0.3mg/dL from peak. In addition, the following criteria must be met: most recent potassium ≤5mEq/L, CKD-EPI SCr-based eGFR reported as ≥15 mL/min/1.73m2, and average SBP ≥120mmHg 12 hours prior to restart. If the study participant is discharged from the hospital before the RASi restart criteria are met, management of RASi restart would be deferred to the discretion of longitudinal outpatient healthcare team.
Usual Care
RASi restart will be deferred to the study participant's providers.
Locations (1)
University of California, San Francisco
San Francisco, California, United States